Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Weltmer

Orthopaedic Surgery Saint Louis, MO Medical Doctor

NPI 1720038052 CMS profile 350841

11125 Dunn Rd, Ste 301, Saint Louis, MO 63136

Open in the dashboard

General payments

$8,583

124 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Weltmer of Saint Louis, MO is reported in the CMS Open Payments database as having received $8,583 across 124 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $396 9
2024 General $2,851 32
2023 General $1,244 18
2022 General $448 8
2021 General $2,389 26
2020 General $297 10
2019 General $958 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Weltmer
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to John Weltmer were reported at $396. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year John Weltmer Orthopaedic Surgery median Middle half National median
2019 $958 $644 $140–$2,844 $163
2020 $297 $312 $75–$1,860 $114
2021 $2,389 $520 $117–$2,495 $132
2022 $448 $598 $128–$2,731 $149
2023 $1,244 $461 $128–$2,264 $160
2024 $2,851 $497 $134–$2,475 $164
2025 $396 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $3,972 32 payments
  2. Elite Orthopedics, LLC $1,678 13 payments
  3. Arthrex, Inc. $1,064 14 payments
  4. Wright Medical Technology, Inc. $229 3 payments
  5. DePuy Synthes Sales Inc. $203 10 payments
  6. 4WEB, Inc. $147 1 payment
  7. Zimmer Biomet Holdings, Inc. $141 9 payments
  8. Integra LifeSciences Corporation $140 1 payment
  9. Treace Medical Concepts, Inc. $111 5 payments
  10. Highridge Medical LLC $104 2 payments
  11. Other $795 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,680 109 payments
  2. Travel and Lodging $3,903 15 payments
Products named General payments · program years 2019–2025
  1. PROSTEP $1,449 11 payments
  2. STAR $544 3 payments
  3. EASYFUSE $410 4 payments
  4. INFINITY $391 3 payments
  5. INBONE $343 1 payment
  6. CITREFIX $197 2 payments
  7. AUGMENT INJECTABLE $166 2 payments
  8. SPINE TRUSS SYSTEM $147 1 payment
  9. PANTA NAIL $140 1 payment
  10. HALLU-LOCK $140 1 payment
  11. Other $2,966 91 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

452

Median for Orthopedic Surgery: 203

Drug cost

$3,792

Median for Orthopedic Surgery: $1,433

Branded share of claims

48%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 105 $1,147
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 112 $1,097
Naproxen Generic 67 $601
Diclofenac Sodium Generic 16 $318
Meloxicam Generic 97 $300
Ibuprofen Generic 12 $123
Tramadol Hcl Generic 24 $118
Gabapentin Generic 19 $88

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$46,241

Of which drugs: $1,245

Medicare patients

145

Average age 69

Services billed

3,027

98 women, 47 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 41%
Diabetes 38%
Ischemic heart disease 30%
Chronic kidney disease 28%
Heart failure 25%
COPD 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 17 2,560 $263

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

124 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record